Case File Banner 24

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

Show Description +

How does treatment burden on patients and caregivers weigh on a provider’s decision to use a durable anti-VEGF agent? Priya Sharma Vakharia, MD, reviews the case of a 73-year-old patient whose family provides transportation to clinic and who has expressed that he feels like a burden to his family. Dr. Vakharia begins therapy with aflibercept (Eylea, Regeneron) before moving to faricimab (Vabysmo, Genentech). After the case is presented, Jordan M. Graff, MD, weighs in on how phase 3 clinical trial data from the TENAYA/LUCERNE studies informs his decision to use faricimab in patients such as this, and Joseph M. Coney, MD, discusses the interconnected nature between dual inhibition, retinal drying, and extended duration.

Posted: 10/03/2023

Up Next

Roundtable: Balancing Safety Concerns With Unmet Needs in Wet AMD and DME Therapy

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Roundtable: Navigating the Treatment Landscape, and a Look at the Pipeline

Ferhina Ali, MD; Ash Abbey, MD; and Scott Walter, MD, MSc,

Roundtable: When and How to Approach Using Newly Approved Anti-VEGF Agents

Priya Sharma Vakharia, MD; Joseph M. Coney, MD; and Yasha S. Modi, MD

Real-World Treatment-Naïve Case: Bilateral Wet AMD in a 92-Year-Old Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Switch Case: Wet AMD Therapy in a Patient Averse to Injections

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Treatment-Naïve Case: Treating DME With a Dual-Inhibition Approach

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-World Step Therapy Case: A Challenging DME Patient

Priya Sharma Vakharia, MD, Joseph M. Coney, MD, and Jordan M. Graff, MD

Real-world Switch Case: Wet AMD Patient Who Relies on Family for Transportation

How does treatment burden on patients and caregivers weigh on a provider’s decision to use a durable anti-VEGF agent? Priya Sharma Vakharia, MD, reviews the case of a 73-year-old patient whose family provides transportation to clinic and who has expressed that he feels like a burden to his family. Dr. Vakharia begins therapy with aflibercept (Eylea, Regeneron) before moving to faricimab (Vabysmo, Genentech). After the case is presented, Jordan M. Graff, MD, weighs in on how phase 3 clinical trial data from the TENAYA/LUCERNE studies informs his decision to use faricimab in patients such as this, and Joseph M. Coney, MD, discusses the interconnected nature between dual inhibition, retinal drying, and extended duration.

Posted: 10/03/2023


Please log in to leave a comment.